The Opportunity
Insitro's mission is to bring better drugs faster to the patients who can benefit most, through machine learning and data at scale. A key part of that mission is to rapidly identify safe and effective molecules that modulate novel targets that emerge from our biology discovery engine. Towards that goal, we have been building a cutting-edge, machine-learning-enabled capability to design and optimize small molecule therapeutics. Our work is enabled by proprietary experimental capabilities, including: generation of extensive binding, selectivity and affinity data via our second generation DNA-encoded library (DEL) platform; rapid synthesis to assay; ML-enabled measurement and analysis of high-content cellular phenotypes driven by small molecule perturbations; and the enablement of active learning via internal lab capabilities and extensive automation. In this role, you will collaborate with our world-class teams in drug discovery, software engineering, lab automation, and cell biology to build a unique approach for rapidly designing and optimizing small molecule therapeutics that have high efficacy, low toxicity and excellent pharmaceutical properties.
In this role, you will:
You will be joining an exciting tech bio startup that has long-term stability due to significant funding, but that is still very much in formation. You will have ample opportunities for growth and impact. You will work closely with a diverse and talented team, learn a broad range of skills, and help shape insitro's culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
About You
Nice to have
Compensation & Benefits at insitro
Our target starting salary for successful US-based applicants for this role is $240,000-$305,000. To determine starting pay, we consider multiple job-related factors including a candidate's skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data.
This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.
In addition, insitro also provides our employees:
insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.
We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.
About insitro insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience, oncology and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com.Yearly based
South San Francisco, CA